These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 21276607)
21. Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patients. Liontos M; Trigka EA; Korkolopoulou P; Tzannis K; Lainakis G; Koutsoukos K; Kostouros E; Lykka M; Papandreou CN; Karavasilis V; Christodoulou C; Papatsoris A; Skolarikos A; Varkarakis I; Adamakis I; Alamanis C; Stravodimos K; Mitropoulos D; Deliveliotis C; Constantinidis CA; Saetta A; Patsouris E; Dimopoulos MΑ; Bamias A World J Urol; 2017 Mar; 35(3):411-419. PubMed ID: 27395374 [TBL] [Abstract][Full Text] [Related]
22. Phosphorylated p70S6K expression is an independent prognosticator for patients with esophageal squamous cell carcinoma. Li SH; Chen CH; Lu HI; Huang WT; Tien WY; Lan YC; Lee CC; Chen YH; Huang HY; Chang AY; Lin WC Surgery; 2015 Mar; 157(3):570-80. PubMed ID: 25726316 [TBL] [Abstract][Full Text] [Related]
23. mTOR/p70S6K signal transduction pathway contributes to osteosarcoma progression and patients' prognosis. Zhou Q; Deng Z; Zhu Y; Long H; Zhang S; Zhao J Med Oncol; 2010 Dec; 27(4):1239-45. PubMed ID: 19936974 [TBL] [Abstract][Full Text] [Related]
24. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma. Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319 [TBL] [Abstract][Full Text] [Related]
25. Phosphorylated Mammalian Target of Rapamycin p-mTOR Is a Favorable Prognostic Factor than mTOR in Gastric Cancer. Cao GD; Xu XY; Zhang JW; Chen B; Xiong MM PLoS One; 2016; 11(12):e0168085. PubMed ID: 28005970 [TBL] [Abstract][Full Text] [Related]
26. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition. Ito H; Ichiyanagi O; Naito S; Bilim VN; Tomita Y; Kato T; Nagaoka A; Tsuchiya N BMC Cancer; 2016 Jul; 16():393. PubMed ID: 27387559 [TBL] [Abstract][Full Text] [Related]
27. Expression of the mammalian target of rapamycin pathway markers in lung adenocarcinoma and squamous cell carcinoma. Kim HS; Kim GY; Lim SJ; Kim YW Pathobiology; 2012; 79(2):84-93. PubMed ID: 22286903 [TBL] [Abstract][Full Text] [Related]
28. Silencing of RHEB inhibits cell proliferation and promotes apoptosis in colorectal cancer cells via inhibition of the mTOR signaling pathway. Tian Y; Shen L; Li F; Yang J; Wan X; Ouyang M J Cell Physiol; 2020 Jan; 235(1):442-453. PubMed ID: 31332784 [TBL] [Abstract][Full Text] [Related]
29. Expression of molecular markers associated with the mammalian target of rapamycin pathway in nonmetastatic renal cell carcinoma: Effect on prognostic outcomes following radical nephrectomy. Nishikawa M; Miyake H; Harada K; Fujisawa M Urol Oncol; 2014 Jan; 32(1):49.e15-21. PubMed ID: 24239474 [TBL] [Abstract][Full Text] [Related]
30. [Correlations between the p-Akt-mTOR-p70S6K pathway and clinicopathological features or chemoresistance of ovarian cancer]. Liu W; Wang Q; Li F; Zhang S; Cao L Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Aug; 42(8):882-888. PubMed ID: 28872078 [TBL] [Abstract][Full Text] [Related]
31. Prognostic impact of the activation status of the Akt/mTOR pathway in synovial sarcoma. Setsu N; Kohashi K; Fushimi F; Endo M; Yamamoto H; Takahashi Y; Yamada Y; Ishii T; Yokoyama K; Iwamoto Y; Oda Y Cancer; 2013 Oct; 119(19):3504-13. PubMed ID: 23861137 [TBL] [Abstract][Full Text] [Related]
32. Phosphorylated mTOR expression correlates with podoplanin expression and high tumor grade in esophageal squamous cell carcinoma. Chuang WY; Chang YS; Chao YK; Yeh CJ; Ueng SH; Chang CY; Liu YH; Tseng CK; Chang HK; Wan YL; Hsueh C Int J Clin Exp Pathol; 2015; 8(10):12757-65. PubMed ID: 26722465 [TBL] [Abstract][Full Text] [Related]
33. [The expression of mTOR and its substrates in oral squamous cell carcinoma]. Liu Y; Yang ML; Zhang Y; Yu BZ Hua Xi Kou Qiang Yi Xue Za Zhi; 2004 Aug; 22(4):331-3. PubMed ID: 15379322 [TBL] [Abstract][Full Text] [Related]
34. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo. Liu J; Zhang L; Zhang X; Xing X J Chemother; 2015; 27(6):358-64. PubMed ID: 25976336 [TBL] [Abstract][Full Text] [Related]
35. Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro. Darb-Esfahani S; Faggad A; Noske A; Weichert W; Buckendahl AC; Müller B; Budczies J; Röske A; Dietel M; Denkert C J Cancer Res Clin Oncol; 2009 Jul; 135(7):933-41. PubMed ID: 19107520 [TBL] [Abstract][Full Text] [Related]
36. [Expression and correlational research of mTOR and 4EBP1 in laryngeal carcinoma]. Zhang X; Ba Y; Song R Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2012 Dec; 26(23):1077-9, 1082. PubMed ID: 23451476 [TBL] [Abstract][Full Text] [Related]
37. NEDD9 overexpression is associated with the progression of and an unfavorable prognosis in epithelial ovarian cancer. Wang H; Mu X; Zhou S; Zhang J; Dai J; Tang L; Xiao L; Duan Z; Jia L; Chen S Hum Pathol; 2014 Feb; 45(2):401-8. PubMed ID: 24439227 [TBL] [Abstract][Full Text] [Related]
38. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. Peponi E; Drakos E; Reyes G; Leventaki V; Rassidakis GZ; Medeiros LJ Am J Pathol; 2006 Dec; 169(6):2171-80. PubMed ID: 17148679 [TBL] [Abstract][Full Text] [Related]
39. Activation of mammalian target of rapamycin pathway confers adverse outcome in nonsmall cell lung carcinoma. Liu D; Huang Y; Chen B; Zeng J; Guo N; Zhang S; Liu L; Xu H; Mo X; Li W Cancer; 2011 Aug; 117(16):3763-73. PubMed ID: 21387259 [TBL] [Abstract][Full Text] [Related]
40. Upregulation of Abelson interactor protein 1 predicts tumor progression and poor outcome in epithelial ovarian cancer. Zhang J; Tang L; Chen Y; Duan Z; Xiao L; Li W; Liu X; Shen L Hum Pathol; 2015 Sep; 46(9):1331-40. PubMed ID: 26193797 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]